Distribution of respective maximum and minimum RMSE test (a,b) and R 2 0 test (c,d) values for the uncorrelated bioactivities 0.5 data set. Average maximum and minimum values of 1.90/0.54 and 0.94/-0.90 were obtained respectively for RMSE test / R 2 0 test with the simulated data. The performance of 10-fold CV PGM models was in agreement with the uncertainty of the experimental measurements, as mean RMSE test and R 2 0 test values of 0.58 pGI 50 unit and 0.79 were obtained. These values are between the two extreme, maximum and minimum, theoretical RMSE test and R 2 0 test values.
7
Distribution of respective maximum and minimum RMSE test (a,b) and R 2 0 test (c,d) values for the complete data set. Average maximum and minimum values of 1.42/0.35 and 0.96/-0.96, were obtained respectively for RMSE test / R 2 0 test with the simulated data. The performance of the 10fold CV PGM models on the test set was in agreement with the uncertainty of the experimental measurements, as mean RMSE test and R 2 0 test values of 0.40 +/-0.00 pGI 50 unit and 0.83 +/-0.00 (with n = 10 models) were obtained. These values are between the two extreme, maximum and minimum, theoretical RMSE test and R 2 0 test values.
8 Supplementary Figure S4 .
Y-scrambling validation. Mean (+/-std) RMSE test (a) and R 2 0 test (b) values were calculated for the observed against the predicted bioactivities on the test set calculated with models trained on pGI 50 values increasingly randomized (n=3). R 2 0 test values become negative when 75% of the bioactivity values are randomized. These data suggest that the relationships established by the 10-fold CV PGM models between compound and cell line descriptors, and the pGI 50 values did not arise from chance correlations. Interpolating compound bioactivities to novel cell lines, tissues, and chemical clusters. (a) Cell line-averaged RMSE test values ranged from 0.41 +/-0.01 (U251) to 0.86 +/-0.01 pGI 50 unit (HOP-92). We found significant differences for tissue-averaged performance (Tukey's HSD, P < 13 Supplementary Figure S7 .
Learning curves. Mean (+/-std) RMSE test (a) and R 2 0 test (b) values were calculated for the observed against the predicted bioactivity values on the test set calculated with n=3 models obtained using training sets covering an increasingly higher fraction of the complete data set.
Models trained on 5% of the data set exhibited a mean RMSE test value of 0.52 pGI 50 unit, which decreased till 0.39 pGI 50 unit when 95% of the data-points were included in the training set.
These data suggest that 10-fold CV PGM models exhibit high interpolation capabilities. In practice, the compound-cell line interaction matrix could be completed with in silico predictions, with a RMSE test value of 0.39 pGI 50 unit. 0 test values of 0.37 pGI 50 unit and 0.87). The color bar indicates the density of points at each region of the plot. For the rest of LOCO and LOTO models comparable results were obtained (Table S11) , with bioactivity values correctly predicted along the whole bioactivity range.
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Supplementary Figure S9
Correlation between observed and predicted pGI 50 values for the 81 drugs present in the complete data set for the following model validation scenarios: (a) LOCO, (b) LOTO, and (c)
LOCCO. The x-axis reports the drug NSC identifiers. Compounds discussed in the main text, namely NSC 630176 and NSC 707389, are marked with asterisks. Bars are colored according to drug mechanism of action (MoA). The abbreviations of the mechanisms of action are: A2: 
Supplementary Figure S10
Validation of conformal prediction. For each confidence level (ε), represented in the x-axis, the number of data-points in the test set which true value lay within the predicted interval is calculated, y-axis. The high Spearman's r s is likely due to the large size of the test set (188,366
data-points) and to the fact that the CI produced by conformal prediction are always valid (Norinder et al., 2014) . These data indicate that the modeling framework combining PGM models and conformal prediction is more information rich than what would be possible with only point prediction algorithms. Figure S11 . 
Consistency between the pathway-drug associations calculated with the experimental and the predicted bioactivity values. For each pathway, we fitted a linear model controlled by tissue source, where the average pathway expression was considered as predictor of drug sensitivity.
Box plots report the distribution of Spearman's rs values between the β p coefficients estimated 
